Welcome to LookChem.com Sign In|Join Free

CAS

  • or

35661-60-0

Post Buying Request

35661-60-0 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

35661-60-0 Usage

Description

Fmoc-L-Leucine, also known as Fmoc-Leu-OH, is an amino acid derivative characterized by its white to light yellow crystal powder appearance. It is a crucial component in peptide chemistry and holds potential as a novel PPARγ ligand, which can activate PPARγ in various ways. This activation has been linked to reduced osteoclast differentiation, making Fmoc-L-Leucine a more promising therapeutic target in diabetes management compared to traditional antidiabetic drugs.

Uses

Used in Pharmaceutical Industry:
Fmoc-L-Leucine is used as a novel PPARγ ligand for its ability to activate PPARγ, which reduces osteoclast differentiation. This property makes it a better therapeutic target in diabetes management compared to traditional antidiabetic drugs.
Used in Peptide Chemistry:
Fmoc-L-Leucine is used as a reactant in the synthesis of various oligopeptides by reacting with functionalized α-amino acid hydrochloride salts. This application is essential in the development of new peptide-based drugs and therapies.
Used in Natural Product Synthesis:
Fmoc-L-Leucine is used as a reactant in the synthesis of cyclic depsipeptide sansalvamide A, a natural product found in marine fungus. This application contributes to the exploration and development of novel bioactive compounds from natural sources.
Used in Antibiotic Production:
Fmoc-L-Leucine is used as a reactant in the synthesis of Streptocidin A-D, a family of decapeptide antibiotics naturally found in Streptomyces sp. Tü 6071. This application aids in the development of new antibiotics to combat drug-resistant bacteria.
Used in Cosmetic Applications:
Fmoc-L-Leucine is used as a reactant in the synthesis of coumaroyl dipeptide amide, a compound with potential applications in the cosmetic industry. This application highlights the versatility of Fmoc-L-Leucine in various industries, including pharmaceuticals, natural product synthesis, antibiotic production, and cosmetics.

Biological Activity

Anti-inflammatory agent; increases intracellular Ca 2+ levels.

Biochem/physiol Actions

PPARγ ligand that induces insulin sensitization, but not adipogenesis.

Check Digit Verification of cas no

The CAS Registry Mumber 35661-60-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,5,6,6 and 1 respectively; the second part has 2 digits, 6 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 35661-60:
(7*3)+(6*5)+(5*6)+(4*6)+(3*1)+(2*6)+(1*0)=120
120 % 10 = 0
So 35661-60-0 is a valid CAS Registry Number.
InChI:InChI=1/C21H23NO4/c1-13(2)11-19(20(23)24)22-21(25)26-12-18-16-9-5-3-7-14(16)15-8-4-6-10-17(15)18/h3-10,13,18-19H,11-12H2,1-2H3,(H,22,25)(H,23,24)/p-1/t19-/m1/s1

35661-60-0 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • TCI America

  • (F0295)  N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-L-leucine  

  • 35661-60-0

  • 1g

  • 130.00CNY

  • Detail
  • TCI America

  • (F0295)  N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-L-leucine  

  • 35661-60-0

  • 5g

  • 150.00CNY

  • Detail
  • TCI America

  • (F0295)  N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-L-leucine  

  • 35661-60-0

  • 25g

  • 450.00CNY

  • Detail
  • Alfa Aesar

  • (B21040)  N-Fmoc-L-leucine, 98%   

  • 35661-60-0

  • 5g

  • 195.0CNY

  • Detail
  • Alfa Aesar

  • (B21040)  N-Fmoc-L-leucine, 98%   

  • 35661-60-0

  • 25g

  • 732.0CNY

  • Detail
  • Aldrich

  • (47633)  Fmoc-Leu-OH  ≥97.0%

  • 35661-60-0

  • 47633-5G-F

  • 269.10CNY

  • Detail
  • Aldrich

  • (47633)  Fmoc-Leu-OH  ≥97.0%

  • 35661-60-0

  • 47633-50G-F

  • 602.55CNY

  • Detail
  • Aldrich

  • (47633)  Fmoc-Leu-OH  ≥97.0%

  • 35661-60-0

  • 47633-250G-F

  • 2,130.57CNY

  • Detail

35661-60-0SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 11, 2017

Revision Date: Aug 11, 2017

1.Identification

1.1 GHS Product identifier

Product name (2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid

1.2 Other means of identification

Product number -
Other names N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-L-leucine

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:35661-60-0 SDS

35661-60-0Relevant articles and documents

Fungal Dioxygenase AsqJ Is Promiscuous and Bimodal: Substrate-Directed Formation of Quinolones versus Quinazolinones

Einsiedler, Manuel,Jamieson, Cooper S.,Maskeri, Mark A.,Houk, Kendall N.,Gulder, Tobias A. M.

supporting information, p. 8297 - 8302 (2021/03/01)

Previous studies showed that the FeII/α-ketoglutarate dependent dioxygenase AsqJ induces a skeletal rearrangement in viridicatin biosynthesis in Aspergillus nidulans, generating a quinolone scaffold from benzo[1,4]diazepine-2,5-dione substrates. We report that AsqJ catalyzes an additional, entirely different reaction, simply by a change in substituent in the benzodiazepinedione substrate. This new mechanism is established by substrate screening, application of functional probes, and computational analysis. AsqJ excises H2CO from the heterocyclic ring structure of suitable benzo[1,4]diazepine-2,5-dione substrates to generate quinazolinones. This novel AsqJ catalysis pathway is governed by a single substituent within the complex substrate. This unique substrate-directed reactivity of AsqJ enables the targeted biocatalytic generation of either quinolones or quinazolinones, two alkaloid frameworks of exceptional biomedical relevance.

Novel chiral stationary phases based on 3,5-dimethyl phenylcarbamoylated β-cyclodextrin combining cinchona alkaloid moiety

Zhu, Lunan,Zhu, Junchen,Sun, Xiaotong,Wu, Yaling,Wang, Huiying,Cheng, Lingping,Shen, Jiawei,Ke, Yanxiong

, p. 1080 - 1090 (2020/05/25)

Novel chiral selectors based on 3,5-dimethyl phenylcarbamoylated β-cyclodextrin connecting quinine (QN) or quinidine (QD) moiety were synthesized and immobilized on silica gel. Their chromatographic performances were investigated by comparing to the 3,5-dimethyl phenylcarbamoylated β-cyclodextrin (β-CD) chiral stationary phase (CSP) and 9-O-(tert-butylcarbamoyl)-QN-based CSP (QN-AX). Fmoc-protected amino acids, chiral drug cloprostenol (which has been successfully employed in veterinary medicine), and neutral chiral analytes were evaluated on CSPs, and the results showed that the novel CSPs characterized as both enantioseparation capabilities of CD-based CSP and QN/QD-based CSPs have broader application range than β-CD-based CSP or QN/QD-based CSPs. It was found that QN/QD moieties play a dominant role in the overall enantioseparation process of Fmoc-amino acids accompanied by the synergistic effect of β-CD moiety, which lead to the different enantioseparation of β-CD-QN-based CSP and β-CD-QD-based CSP. Furthermore, new CSPs retain extraordinary enantioseparation of cyclodextrin-based CSP for some neutral analytes on normal phase and even exhibit better enantioseparation than the corresponding β-CD-based CSP for certain samples.

Unwanted hydrolysis or α/β-peptide bond formation: How long should the rate-limiting coupling step take?

Goldschmidt G?z, Viktória,Nagy, Adrienn,Farkas, Viktor,Keszei, Ern?,Perczel, András

, p. 30720 - 30728 (2019/10/28)

Nowadays, in Solid Phase Peptide Synthesis (SPPS), being either manual, automated, continuous flow or microwave-assisted, the reaction with various coupling reagents takes place via in situ active ester formation. In this study, the formation and stability of these key active esters were investigated with time-resolved 1H NMR by using the common PyBOP/DIEA and HOBt/DIC coupling reagents for both α- and β-amino acids. Parallel to the amide bond formation, the hydrolysis of the α/β-active esters, a side reaction that is a considerable efficacy limiting factor, was studied. Based on the chemical nature/constitution of the active esters, three amino acid categories were determined: (i) the rapidly hydrolyzing ones (t 24 h) in solution. The current insight into the kinetics of this key hydrolysis side reaction serves as a guide to optimize the coupling conditions of α- and β-amino acids, thereby saving time and minimizing the amounts of reagents and amino acids to be used-all key factors of more environmentally friendly chemistry.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 35661-60-0